(Q46399777)

English

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

scientific article published in January 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

1 reference

based on heuristic

inferred from title

author name string

A John Rush

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

Anjana Bose

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

21

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

26-32

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram continuation treatment prevents relapse of depressive episodes

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

The measurement of disability.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1002%2FDA.20051

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20051

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786487

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46399777&oldid=2109645141"